BCL2 and myelodysplastic syndrome: Prospective studies that integrate quantitative BCL-2 immunohistochemistry with comprehensive mutational profiling upon diagnosis are warranted to clarify whether low-blast MDS cases with high BCL-2 expression harbor adverse driver mutations and to determine their potential sensitivity to BCL-2-directed therapy.